Jin Bihui, Qian Lingbo, Fu Xiaohua, Zhu Jing, Shu Jing
Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
School of Basic Medical Sciences & Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China.
J Int Med Res. 2020 Aug;48(8):300060520935313. doi: 10.1177/0300060520935313.
Observational studies have shown that circulating vitamin D (VitD) deficiency is associated with atherogenic lipid patterns among polycystic ovary syndrome (PCOS) patients. However, interventional studies have shown inconsistent results. The aim of this meta-analysis was to investigate how VitD supplementation influences lipid indices in PCOS patients.
The authors searched four electronic databases through August 2019 to identify randomized controlled trials (RCTs) that assessed the effect of VitD intervention on serum lipids among PCOS patients. Mean differences were generated for statistical evaluation.
We included eight studies and performed nine comparisons across 467 participants. VitD supplementation reduced serum triglyceride levels (-11.88 mg/dL; 95% confidence interval [CI]: -17.03 to -6.73), total cholesterol (-9.09 mg/dL; 95% CI: -14.90 to -3.29), low-density lipoprotein cholesterol (-5.22 mg/dL; 95% CI: -10.32 to -0.13), and very-low-density lipoprotein cholesterol (-2.43 mg/dL; 95% CI: -3.69 to -1.17) compared with no VitD supplementation. However, high-density lipoprotein cholesterol levels showed no differences with or without VitD supplementation (-0.39 mg/dL; 95% CI: -1.39 to 0.61).
VitD supplementation improved serum lipid levels among PCOS patients, but serum high-density lipoprotein cholesterol levels were not changed. VitD intervention might benefit PCOS patients who are at high risk of an atherogenic lipid profile.
观察性研究表明，多囊卵巢综合征（PCOS）患者循环维生素D（VitD）缺乏与致动脉粥样硬化血脂模式相关。然而，干预性研究结果并不一致。本荟萃分析的目的是研究补充VitD如何影响PCOS患者的血脂指标。
作者检索了截至2019年8月的四个电子数据库，以确定评估VitD干预对PCOS患者血脂影响的随机对照试验（RCT）。生成平均差异进行统计学评估。
我们纳入了八项研究，对467名参与者进行了九次比较。与不补充VitD相比，补充VitD可降低血清甘油三酯水平（-11.88mg/dL；95%置信区间[CI]：-17.03至-6.73）、总胆固醇（-9.09mg/dL；95%CI：-14.90至-3.29）、低密度脂蛋白胆固醇（-5.22mg/dL；95%CI：-10.32至-0.13）和极低密度脂蛋白胆固醇（-2.43mg/dL；95%CI：-3.69至-1.17）。然而，补充或不补充VitD时高密度脂蛋白胆固醇水平无差异（-0.39mg/dL；95%CI：-1.39至0.61）。
补充VitD可改善PCOS患者的血脂水平，但血清高密度脂蛋白胆固醇水平未改变。VitD干预可能使具有致动脉粥样硬化血脂谱高风险的PCOS患者受益。
